Vermillion Inc announces the reappointment of Gail S. Page as Chief Executive Officer of the Company and Eric T. Fung, MD, PhD as Senior Vice President and Chief Science Officer of the Company.

In addition, the previously announced appointment of William C. Wallen, PhD to the Board of Directors is now effective. Page will continue to act as Chair of the Board of Directors.

"Both Dr. Fung and I are pleased to resume our positions and are excited to launch the OVA1(TM) test this quarter, our first FDA cleared commercial product," Page said. "We look forward to expanding our ovarian program and making continued progress on our peripheral artery disease program."

Page joined the company in 2004 as President to lead the formation of the Diagnostics division. From December 2005 to March 2009, she served as President and Chief Executive Officer. On March 27, 2009, Page was appointed Executive Chair and was responsible for leading Vermillion through the successful reorganization and exit from Chapter 11. Page has been a member of the Board of Directors since 2006.

Dr Fung originally joined Vermillion in May 2000 as a lead scientist in the Biomarker Discovery Centers and was promoted to VP and Chief Scientific Officer in June 2006. He was responsible for leading the successful OVA1™ prospective clinical trial. He resigned in March 2009, and returned after the clearance of OVA1™ in a consulting capacity to advise the company in all medical and clinical aspects.

Dr William Wallen was appointed to the Board of Directors on December 10, 2009. He is currently the Chief Scientific Officer, Senior Vice President for Research and Development for IDEXX Laboratories and previously served on Vermillion’s Scientific Advisory Board.